A Review and Analysis of the YODA Trials: What Can We Glean Clinically?
Authors:
Open Access
- 6 June 2014
- journal article
- review article
- Published by Springer Nature in Current Reviews in Musculoskeletal Medicine
- Vol. 7 (3) , 189-192
Abstract
Medtronic's biologic, Infuse (rhBMP-2), was approved by the FDA in 2002. Since its approval, a whirlwind of controversy developed culminating in an investigation by the Senate Finance committee. These events led to a landmark agreement between Medtronic and Yale University to perform a comprehensive and unbiased analysis of all patient related data. The project was named the Yale Open Data Access (YODA). The purpose of this article is to evaluate the results of the YODA project and determine what is clinically meaningful.Keywords
This publication has 8 references indexed in Scilit:
- Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine FusionAnnals of Internal Medicine, 2013
- Safety and Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 for Spinal FusionAnnals of Internal Medicine, 2013
- A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learnedThe Spine Journal, 2011
- Lumbar posterolateral fusion with local bone graft plus bone extender compared with iliac crest bone graft: a systematic reviewEvidence-Based Spine-Care Journal, 2011
- Single-level instrumented posterolateral fusion of the lumbar spine with a local bone graft versus an iliac crest bone graft: a prospective, randomized study with a 2-year follow-upEuropean Spine Journal, 2010
- Off-Label Use of Bone Morphogenetic Proteins in the United States Using Administrative DataSpine, 2010
- Ratings of global outcome at the first post-operative assessment after spinal surgery: how often do the surgeon and patient agree?European Spine Journal, 2009
- Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine FusionSpine, 2006